Acne is a chronic inflammatory skin disease that involves the pathogenesis of four major factors, such as androgen-induced increased sebum secretion, altered keratinization, colonization of Propionibacterium acnes, and inflammation. Several acne mono-treatment and combination treatment regimens are available and prescribed in the Indian market, ranging from retinoids, benzoyl peroxide (BPO), anti-infectives, and other miscellaneous agents. Although standard guidelines and recommendations overview the management of mild, moderate, and severe acne, relevance and positioning of each category of pharmacotherapy available in Indian market are still unexplained. The present article discusses the available topical and oral acne therapies and the challenges associated with the overall management of acne in India and suggestions and recommendations by the Indian dermatologists. The experts opined that among topical therapies, the combination therapies are preferred over monotherapy due to associated lower efficacy, poor tolerability, safety issues, adverse effects, and emerging bacterial resistance. Retinoids are preferred in comedonal acne and as maintenance therapy. In case of poor response, combination therapies BPO-retinoid or retinoid-antibacterials in papulopustular acne and retinoid-BPO or BPO-antibacterials in pustular-nodular acne are recommended. Oral agents are generally recommended for severe acne. Low-dose retinoids are economical and have better patient acceptance. Antibiotics should be prescribed till the inflammation is clinically visible. Antiandrogen therapy should be given to women with high androgen levels and are added to regimen to regularize the menstrual cycle. In late-onset hyperandrogenism, oral corticosteroids should be used. The experts recommended that an early initiation of therapy is directly proportional to effective therapeutic outcomes and prevent complications.
Introduction
Acne vulgaris is a chronic condition that affects quality of life adversely in about 85% of adolescents and 66.7% of adults. [1] [2] [3] It starts with the obstruction of pilosebaceous unit, resulting in the formation of comedones (noninflammatory), followed by progression to inflammatory acne that includes papules, pustules, nodules, and cysts. [4] The major causal factors involve altered sebum levels (androgen-driven), changes in keratinization, and bacterial colonization of the pilosebaceous units on the face, neck, chest, and back. [5] It is essential to assess severity of acne as well as the individual patient factors for acne management.
recommendations by the dermatologists' panel across India who held discussions in an order to practically define positioning of different market formulations in acne management, address when to prefer monotherapy or combination therapy with rationality of available combinations, review within class and comparison of strength of different available molecules, and consider formulation innovations along with the role of the adjunctive treatments.
Management of Acne using Topical Agents

Monotherapy
Retinoids
Retinoids have a potential role in decreasing sebum production along with in-regulation of desquamation and adhesion of keratinocyte, thus resulting in comedolysis and suppression of new microcomedonal development. [9] [10] [11] [12] They are a preferred choice for scars and postinflammatory hyperpigmentation (PIH) of the skin. [9, 13, 14] Tretinoin, isotretinoin, adapalene, and tazarotene are considered as the first choice of treatment and maintenance therapy. Topical retinoids are used as monotherapy in noninflammatory acne and in combination with other topical agents in inflammatory and more severe forms of acne. [15] [16] [17] [18] [19] However, flaring up of acne during initial weeks of treatment limits its use or warrants combination with other agents [Tables 2 and 3 ]. [20, 21] Expert opinion Place of therapy Micronized topical retinoids are a preferred choice, where adapalene (0.1%) is considered as the first-line therapy. Adapalene gel (0.3%) may have future relevance as maintenance therapy in patients with acne scars. Tretinoin is preferred in the trunk, back, and arm acne for priming before peels and lasers during maintenance phase. However, it should be stopped 2-3 days and 5-6 days before these procedures, respectively. The relevant strengths of tretinoin that are used in India are 0.025% and 0.05% and as micronized formulation (0.1%). Tazarotene, due to poor tolerance, is usually not used in Indian acne management. Isotretinoin is not preferred topically, whereas retinol and retinaldehyde may be used as maintenance therapy due to better tolerance. They [88] 12 weeks; randomized parallel group study Topical Isotret more effective, Ada better tolerated
Tret microsphere gel pump (0.04%) versus Taz cream (0.05%); mild to moderate acne [89] 12 weeks; single-center, investigator-blinded, randomized, parallel-design study
Comparable efficacy, ADRs significantly lesser in microsphere group Ada (0.1%) gel versus daily Taz (0.1%) cream; acne type not specified (n=202) [90] 12 weeks; randomized, evaluator-blinded study Ada noninferior to Taz, better tolerated with low ADRs Ada gel (0.1%) in subjects successfully treated with Ada-Doxy (100 mg); Severe acne (n=253) [91] 16 weeks; multicenter, investigator-blind, randomized, controlled study Clinical benefit observed with Ada Ada (0.1%) gel versus BPO (2.5%) gel; mild acne (n=60) [92] 2 months study period, 3 months follow-up; single-center, randomized, double-blind, clinical trial
Comparable safety and efficacy; Ada slightly better Ada (0.1%) versus BPO (4%); mild to moderate acne (n=200) [93] 12 weeks; open clinical trial (interventional quasi-experimental study) Equivalent safety and efficacy, BPO better for inflammatory while Ada for comedonal acne Ada gel (0.1%) versus Tret gel (0.025%); moderate to severe acne (n=150) [94] 8 weeks; randomized (comparative) study Comparable efficacy, Ada better tolerated Antibacterials Azithro (2%) gel with Clin (1%) gel; mild to moderate acne (n=40) [95] 8 weeks; double-blind clinical trial Azithro similar to Clin; suitable for resistant acne Nadi (1%) cream versus Erythro (4%) gel; mild to moderate acne (n=86) [96] 12 weeks; comparative study Comparable safety and efficacy
Clin nano-emulsion gel (1%); (n=200); acne vulgaris-type not specified [97] 12 weeks; prospective, active-controlled, multicenter, Phase IV clinical trial Clin nano-gel more effective than conventional gel Nadi (1%) cream; mild to moderate acne [98] 8 weeks; randomized, prospective, split-face, double-blind, vehicle-controlled trial Effective, safe, and well-tolerated Azithro versus topical solutions of Clin and Erythro; mild to moderate acne (n=96) [99] 20 weeks; randomized double-blind clinical trial Azithro better in efficacy but inferior in tolerability Nicotin (4%) versus Clin (1%) topical gels; moderate inflammatory acne (n=75) [42] 8 weeks; double-blind investigation Comparable efficacy BPO Topical BPO (n=2818) [100] Systematic review of randomized vehicle-controlled trials
Reduced acne lesions, noninflammatory lesions, and inflammatory lesions BPO (3%) gel versus an inert vehicle gel (n=361) [101] 12 weeks; multicenter, randomized, double-blind, vehicle-controlled, parallel-group study Effective, favorable safety, and tolerability profile Ada: Adapalene, Isotret: Isotretinoin, Tret: Tretinoin, Taz: Tazarotene, ADRs: Adverse drug reactions, Doxy: Doxycycline, BPO: Benzoyl peroxide, Azithro: Azithromycin, Clin: Clindamycin, Nadi: Nadifloxacin, Erythro: Erythromycin, Nicotin: Nicotinamide can also contribute to antiaging effects and combined with antioxidant Vitamins C and E. Application All retinoids are prescribed once a day in the evening or at night. They should be applied after washing face with a mild cleanser (cetyl/stearyl alcohol based) and drying completely. After 10 min, retinoids formulation should be applied on the whole face without rubbing/massaging. If moisturizer is being used, they should be applied immediately after the moisturizer application. Short contact therapy with initial ½ h application, then 1 h, and then overnight application is recommended to decrease irritation and retinoid dermatitis (dryness).
Maintenance therapy Maintenance therapy is recommended after resolution of all visible lesions to treat microcomedones and to prevent acne flare-up or recurrence. Treatment duration should last until a 6-month acne-free period on maintenance therapy is achieved. Retinoid maintenance treatment may be tapered down to twice/thrice a week, the frequency depending on the tell-tale remnant signs of the primary lesions such as comedones and pigmentation.
Antibacterials
Antibacterials act potentially against Propionibacterium acnes, the most common causal organism in acne, and possess surface-acting capability; hence, they can prevent the formation of inflammatory lesions on the skin surface. [22] Topical antibiotics are recommended for the treatment of mild to moderate acne (inflammatory lesions) [ Table 2 and 3].
Expert opinion
Clindamycin and nadifloxacin are currently preferred in combinations with retinoids or benzoyl peroxide (BPO). Nadifloxacin has potential advantages and comparable efficacy with clindamycin, effect on biofilms, absence of documented resistance, and relative protection from Gram-negative folliculitis (GNF) due to broad-spectrum coverage. [23, 24] Erythromycin and clarithromycin are not preferred currently in Indian acne practice. Lincomycin (2%) gel is also available though market is low and not seeming under active promotion. Triclosan is not preferred due to carcinogenic potential, and it may have some role in scabies. In acne pathogens, i.e., P. acnes, Staphylococcus epidermidis, Staphylococcus aureus, methicillin-resistant S. aureus, and Malassezia furfur, M. furfur back acne is treated using itraconazole (twice daily; BID 100 mg for 14 days) after doing hematological and liver function test.
Benzoyl peroxide BPO is a nonantibiotic antimicrobial agent that allows generation of reactive oxygen species within the follicle and thus elicits bactericidal properties. It is effective for the treatment of inflammatory lesions and provides protection from antibiotic resistance [ Tables 2 and 3] . [16, [23] [24] [25] Some guidelines suggest systematic approach along with the utilization of BPO mainly in case of inflammatory lesions. [5, 9, 26] Expert opinion BPO (2.5%) is preferred over 5% strength due to comparable efficacy and better tolerance. Plain BPO may be used in newly diagnosed adolescent mild acne and as topical application in patients on systemic isotretinoin. In other cases, combination of BPO with adapalene or antibacterials is used. BPO (5%) with sulfur is reserved for resistant back, arm, and trunk acne. It has been suggested to use it ½ h before bath due to its odor. Coacrylate polymer gels or microencapsulated gels should be preferred for better stability and tolerance.
Combination therapy
Combination therapies are preferred to avoid skin sensitization, antibiotic resistance as well as to enhance the treatment outcomes. [9, 24, [26] [27] [28] [29] [30] [31] Multimodal therapy targeting different pathological processes, simultaneously, leads to a better outcome due to synergistic effects. [32] Studies also report that combination therapy plays a role in improving patient adherence due to incorporation of simplified and personalized daily regimen. [32, 33] Table 2 enlists various combination therapies available in the market.
Antibacterial-retinoid
The combination therapy of topical retinoid and antibiotic is an essential treatment measure and is contemplated as the first-line therapy for the treatment of moderate to severe acne. Retinoids assist penetration of antibacterials into the pilosebaceous unit (colonization site for P. acnes), hence allowing better efficacy [ Table 4 ]. [31, 34] Expert opinion BPO-antibacterials are recommended for pustule-nodular acne, whereas BPO-retinoid/antibacterial-retinoids are prescribed in comedonal papulopustular acne. Antibacterial-retinoids may be prescribed, especially if perceived tolerance with BPO-retinoid combinations is poor, formulation technology (microencapsulation) can determine the choice.
Antibacterial-benzoyl peroxide
The keratolytic action of BPO enhances the antibacterial activity of antibacterials. Further, the bactericidal properties of BPO help in reduction of microbial resistance to the topical antibiotics [ Table 4 ]. [24, 25, 35, 36] Expert opinion BPO-antibacterial combination may be prescribed in acute inflammatory acne (with large number of pustules) or moderate acne tending to severe acne for early lesion control. It can potentiate action on biofilms and can be given in morning with adapalene at night.
It may also be prescribed as topical therapy in patients on systemic isotretinoin and when topical retinoids are not tolerated.
Adapalene (retinoid)-benzoyl peroxide
In mild to moderate acne, adapalene-BPO is the most preferred combination and used as the first-line [103] 12 weeks; multicenter, randomized, investigator-blind, parallel-group study Taz + Clin greater efficacy, but comparable tolerability
Clin phosphate (1.2%) + Tret (0.025%); mild to severe acne (n=4550) [104] Pooled analysis of three pivotal studies
Combination better as first-line treatment; easily handled and applied; no bleaching effects, quick onset of action and better success rates Ada (0.1%) + Clin (1%) nano-emulsion gel versus conventional formulation; acne vulgaris -type not specified (n=212) [105] 12 weeks; prospective, randomized, open-label, active-controlled, multicenter, Phase IV clinical trial Nano-emulsion gel formulation effective and better tolerated Antibacterial-BPO Clin+BPO gel versus Ada + BPO gel; mild to moderate acne (n=76) [106] 8 weeks; randomized, single-blind, split-face study Clin + BPO gel better tolerated during the first 2 weeks of treatment; comparable efficacy at 8 weeks BPO+Clin versus BPO+Nadi versus Tret+Clin; moderate to severe acne (n=100) [107] 12 weeks; prospective, open-labeled, randomized, comparative drug study Clin + BPO better in reduction of lesion count; safety profile better with Nadi + BPO Nadi (1%) versus Clin (1%) as add-on therapy to BPO (2.5%); mild to moderate acne (n=84) [108] 8 weeks; randomized controlled assessor blind trial Both the regimens were comparable Clin+BPO versus Clin alone; mild to moderate acne (n=80) [35] 6 weeks; randomized open-label study Clin+BPO more effective; cutaneous ADR observed in both the groups Clin (1%) + BPO (5%) gel versus Clin 1% preparations (gel, lotion, and solution) (n=80) [109] 2 weeks; open-label comparative study Clin+BPO gel more effective Nadi versus Nadi + BPO; mild to moderate acne (n=93) [110] 8 weeks; randomized, double-blind, parallel group study Both regimens effective, well-tolerated; inflammatory lesions better reduced in the Nadi + BPO group BPO (5%) + Clin phosphate (1%) gel versus Clin phosphate (1.2%) + Tret (0.025%) gel; mild to moderate acne (n=541) [111] 6 weeks; two-center, investigator-blinded, randomized, parallel-group study Clin phosphate + BPO gel better than Clin phosphate + Tret BPO (5%) + Clin versus BPO (2.5%) + Clin; mild to moderate acne (n=4960) [112] Meta-analysis of 16 RCTs Comparative efficacy
Retinoid-BPO Ada (0.1%) + BPO (2.5%); moderate to severe acne (n=5131 for efficacy, n=5141 for safety) [113] 9 months; noninterventional cohort study Safe and effective in the long-term management of acne patients Ada (0.1%) + BPO (2.5%) FDC gel; acne vulgaris -type not specified (n=2300) [114] 4 weeks; meta-analysis of 14 clinical studies Effective and well tolerated Ada (0.1%) + BPO (2.5%) FDC gel; Papular-pustular acne (n=79) [115] 12 weeks; multicenter, open-label and interventionist study Effective, safe, well-tolerated, and better patient compliance Ada (0.3%) + BPO (2.5%), a new FDC gel; moderate to severe inflammatory acne (n=503) [116] 12 weeks; multicenter, randomized, double-blind, parallel-group study 0.3% Ada+BPO had significantly greater efficacy (P=0.029); 0.1% Ada+BPO did not reach statistical significance (P=0.443). 0.3% Ada + BPO was safe and well-tolerated Ada (0.1%) + BPO (2.5%) versus vehicle; moderate inflammatory acne (n=31) [117] 6 months; multicenter, randomized, investigator-blinded, vehicle-controlled, split-face study Long-term treatment with Ada + BPO reduced the risk of atrophic scars and improved the global severity of scarring Nadi: Nadifloxacin, Ada: Adapalene, ADRs: Adverse drug reactions, FDC: Fixed dose formulation, Taz: Tazarotene, Clin: Clindamycin, Tret: Tretinoin, BPO: Benzoyl peroxide, RCTs: Randomized controlled trials therapy. [30] The relapses in severe and moderate to severe acne patients can be prevented with the use of adapalene-BPO combination as maintenance therapy (for 6-12 months) subsequent to treatment with oral isotretinoin. [37, 38] Combination of BPO with other retinoids is found to be unstable and hence avoided [ Table 4 ]. [29] Expert opinion Adapalene-BPO is the most preferred combination and used as the initial and first-line therapy in mild-moderate inflammatory acne (mainly comedones with few papules/pustules). This is also preferred in maintenance phase over retinoid monotherapy to tackle intermittent activity and flare-ups.
Miscellaneous Agents
Niacinamide
The inhibitory action of niacinamide on sebocyte secretions results in less sebum production and reduced oiliness of the skin. [39, 40] It is beneficial in pustular as well as papular acne due to its anti-inflammatory properties [41] and is also a choice of treatment in cases with antimicrobial resistance [ Tables 2 and 5 ]. [42, 43] Expert opinion For active treatment, niacinamide (4%) in dermato-cosmetic mattifying creams are used for daytime use and retinoids/BPO/anti-infective combinations are used at night time. During maintenance therapy, combination with adapalene is preferred for daytime use. It is also used in the cases of PIH for skin lightening and for patients with oily skin.
Dapsone
Dapsone is used in acne due to its antibacterial and anti-inflammatory activity. Its low cost makes it affordable and available to acne patients in developing countries. [44] [45] [46] Topical gel of dapsone (5%) is usually used to treat inflammatory and noninflammatory acne lesions. [47] Expert opinion Dapsone is used more of an elimination molecule due to intolerance or inadequate response to BPO/retinoids in inflammatory acne (effect seen only after 6 weeks). However, it has efficient action in scalp folliculitis and acne inversa (given twice a day with adapalene-BPO at night time).
Azelaic acid
Azelaic acid inhibits protein synthesis of the P. acnes species without bacterial resistance. [48, 49] Its bacteriostatic, anti-inflammatory, antioxidant, and antikeratinizing properties enhance its antiacne potential. [50] Its combination with clindamycin 1% gel, BPO 4% gel, and tretinoin 0.025% cream is an effective acne treatment regimen. [30, 51] Expert opinion It is effective but its use is limited due to unpredictable irritation and it has been suggested to consider liposomal preparation. Initially, 10% strength is given which is then scaled up to approximately 20%. However, it is not recommended in fixed-dose combinations. It is preferred as a morning application in acne with pigmentation along with retinoid combination in the evening.
Zinc
Zinc in combination with or without nicotinamide has been recommended as a budding alternate acne treatment with reduced adverse effects (AEs) of antibiotics. It has anti-inflammatory activity and inhibits the P. acnes lipases and free fatty acids, thereby reducing the P. acnes counts. [52] Furthermore, it is found to possess antiandrogenic activity which enables in suppression of sebum levels. [53] Its combination with antibiotics facilitates antibiotic absorption as well. [52, 54] Expert opinion Role of zinc is not established. Its salts with pyrrolidone carboxylic acid and gluconate may be used in the combination dermato-cosmetic products with niacinamide and soothing agents.
Hydroxy acids
Glycolic acid (alpha hydroxy acid) and salicylic acid (beta hydroxy acid) are used as chemical peels for facial resurfacing. They mainly act by stimulating reepithelialization and skin rejuvenation. [3, 44] However, they are not recommended as the first-line treatment for acne due to safety issues. [44, 55] Expert opinion Glycolic acid is used as a cream with 6% and 12% concentration. It may also be used in highly comedonal acne and in the presence of pigmentation. Salicylic acid (2%) may have a role as supportive therapy in acne maintenance. Keratolytic action below 3% is uncertain, and it may actually be keratoplastic. It is mostly used as face wash.
Herbal Agents
Since ancient times, the herbal therapies such as Yarrow (Achillea millefolium), Aloe vera (Aloe barbadensis), Burdock (Arctium lappa), Wormwood (Artemisia absinthium), Neem (Azadirachta indica), Barberry (Berberis vulgaris), False unicorn (Chamaelirium luteum), and Goldthread (Coptis chinensis) are being used for the treatment of acne. [56, 57] These agents are found to have anti-inflammatory, moisturizing, and soothing properties. [22] [118] 8 weeks; investigation study Significant efficacy in reduction of inflammatory and noninflammatory lesions Topical (2%); (n=100; n=30) [40] 2 clinical trials: 4 weeks; double-blind, placebo-controlled comparison between two independent balanced groups 6 weeks; randomized split-face study Effective in lowering the sebum excretion rate and casual sebum levels Nia (4%) versus Clin (1%); moderate inflammatory acne (n=80) [43] 8 weeks; randomized, double-blind clinical trial Both were significantly efficacious in oily and nonoily skin types Dap 7.5% gel versus higher concentration (50%) versus vehicle; moderate acne (n=2102) [119] 12 weeks; randomized, double-blind, vehicle-controlled, multicenter clinical trial Dap (7.5%, once daily) effective, safe, and well-tolerated Gel (5%); acne vulgaris -type not specified (n=68) [120] 12 weeks; multicenter, open-label, single-group, pilot study
Safe and effective
Dap gel (5%) + Ada (0.1%) gel or BPO (4%) gel or moisturizer; acne vulgaris -type not specified (n=301) [121] 12 weeks; randomized, double-blind study Dap + Ada and Dap + BPO were safe and well tolerated Dap (5%) gel versus Clin (1%) gel; mild to moderate acne (n=60) [122] 12 weeks; comparative evaluation Dap better than Clin
Azelaic acid Gel (15%); mild to moderate acne (n=20) [123] 16 weeks; single-center, open-label study
Twice daily application effective in acne and PIH AzA (15%) versus Ada (0.1%) gel; resistant and relapsing adult acne (n=55) [124] 9 months; investigator-blind trial AzA (15%) gel is a safe, effective and maintenance treatment Zinc Erythro (4%) + zinc (1.2%) versus Clin (1%); acne vulgaris -type not specified (n=103) [125] 12 weeks; RCT Erythro/zinc has higher efficacy than Clin Erythro (4%) + zinc (1.2%); (n=14) [53] 3 months; double-blind randomized study
Significant reduction in sebum output
Complex of seaweed-derived oligosaccharide and zinc pyrrolidone (0.1%); mild acne (n=60) [126] 8 weeks; double-blind, vehicle-controlled trial Significant reduction in acne Glycolic acid GA (10%) oil-in-water emulsion; mild acne (n=120) [127] 90 days; double-blind, placebo-controlled, randomized, monocenter trial Improvement in mild acne and well tolerated GA (35% and 50%) peels and GA (15%) home care products; moderate to moderately severe acne (n=40) [128] 12 weeks GA has considerable therapeutic value GA (70%) chemical peels; all types of acne (n=80) [129] 1 year 11 months Effective treatment for all types of acne GA peels versus GA cream; atrophic acne scars (n=58) [130] 24 weeks; single, blind, placebo-controlled, randomized comparative clinical study GA peels effective for acne treatment; GA cream beneficial for patients nontolerable to peels GA (12%) versus AzA (10%); acne vulgaris -type not specified (n=30) [131] 12 weeks; prospective study Comparable efficacy; constant decline in PIH with GA GA (6%) + retinaldehyde (0.1%) cream; Moderate acne (n=145) [132] 3 months; double-blind vehicle-controlled study Efficient therapy for acne prevention as well as treatment Salicylic acid SA (30%) peels; acne vulgaris -type not specified (n=35) [133] 12 weeks Effective and safe therapy Contd...
Expert opinion
For herbal preparations, substantiating data are poor; A. vera as a soothing agent may have some acceptance. Sulfur is used for back acne ½ h before bath, but it is not prescribed for facial acne.
Other Suggestions/Recommendations by Experts
Postinflammatory hyperpigmentation
PIH, also known as acne hyperpigmented macule, is an acquired hypermelanosis that occurs due to inflammation or injury to the cutaneous and can affect all types of skin. It mainly affects the skin color of patients and is widespread in people with darker skin. Basically, PIH is observed in the areas of acne papules, pustules, and nodules. Moreover, the intensity of PIH is based on the severity of inflammation and the type of skin. [59, 60] Expert opinion on postinflammatory hyperpigmentation Sunscreen and removal of triggering factors should be implemented in all patients. Hydroquinone (2/4%) or triple-agent therapy (hydroquinone/tretinoin/fluocinolone), kojic acid and Vitamin C, azelaic acid, topical retinoids (adapalene/tretinoin/tazarotene) are used as the first-line therapy. Chemical peels (glycolic acid, salicylic acid) are recommended as the second-line therapy while laser therapy can be considered as the third-line therapy. These therapies are used along with regular antiacne treatment. The duration of treatment is variable; most patients respond 6-8 weeks after the therapy. Although skin lighting is an additional advantage with azelaic acid and topical retinoids, tolerability (irritation and dryness) limits their use; concerns more with Indian skin.
Face wash
Face washes used with retinoids should be a mild cleanser. Cetyl, stearyl alcohol should be used for mild cleansing property without exfoliative/acidic component. BPO cleansers and foams may be used in truncal acne. For acne maintenance, salicylic acid (2%) is the most preferred, whereas glycolic acid (1%) can be used as an exfoliator, but it may increase irritation. A 2-min contact time for face wash is advised.
Application do's and don'ts
Azelaic acid, glycolic acid, retinoids, plain BPO, and BPO-retinoid combination should be applied on full face, whereas antibacterials and their combination with BPO should be applied on lesions. Massaging and rubbing are not recommended. Gels are preferred over creams. Creams may be used in very dry weather (winter) or in case of skin dryness in response to retinoids. Moisturizer (noncomedogenic, nongreasy, nonsticky, and nonfragrant) should be applied after face wash on dry face, twice daily, whereas antidandruff shampoo has been recommended to be used twice weekly. Some miscellaneous points discussed by experts are presented in Figure 1 .
Management of Acne using Oral Agents
Isotretinoin (retinoid)
Currently, isotretinoin is the only oral retinoid available in India for the treatment of acne. Isotretinoin targets the four major factors involved in the mechanism of acne owing to the following effects, viz., stabilizing the follicular desquamation, suppressing the sebum production, preventing the P. acnes growth, and allowing anti-inflammatory action [ Tables 2 and 6 ]. [7, 19, 60] Expert opinion Although the literature recommendation is for severe nodular acne, in real-life practice, isotretinoin is used earlier in the treatment of acne (moderate-severe). A cumulative dose of 120-150 mg/kg isotretinoin is the best treatment regimen for moderate to severe acne. If patients relapse (0.5-1 mg/kg) after achieving target cumulative dose (120-150 mg/kg), repeat cycle should be given at a double dose (1-2 mg/kg). Overall, low-dose regimens (0.3-0.4 mg/kg) are economical and have better patient acceptance. Due to early response or improvement after starting isotretinoin, patients may not come back for follow-up and stop therapy on their own leading to relapses as cumulative required dose is not reached.
Macrocomedonal flare-up is observed in 20%-30% cases during isotretinoin treatment and should be handled with patient counseling and using a low-dose isotretinoin or addition of pulse dose of azithromycin. It lasts for almost 4-5 weeks and usually does not [134] Comparative study SA peels more effective BPO (5%) versus Clin (1%-1.2%) versus BPO (5%) + SA versus BPO + Clin; acne vulgaristype not specified (n=7309) [135] Meta Isotret (fixed-dose, 10 mg daily); moderate to severe acne (n=150) [136] 4 years; prospective study Safe and low relapse rate Isotret (low-dose, 20 mg/day); moderate to severe acne (n=50) [137] 3 months; prospective, noncomparative study
Effective and economical
Isotret (low-dose) + Azithro (pulsed oral); moderate to severe acne (n=82) [138] 24 weeks; open-label, noncomparative study
Effective combination for treating acne Isotret effects on physical and psychosocial status, as well as the treatment satisfaction level; moderate acne (n=346) [139] 30 weeks; prospective, observational, longitudinal study
Positive impact on QOL Isotret (low-dose versus intermittent); moderate acne (n=60) [140] 24 weeks treatment and 1 year follow-up; randomized, controlled comparative study
Low-dose Isotret suitable in terms of tolerability, efficacy and patient satisfaction Isotret (daily, alternate, pulse and low-dose regimens); mild to moderate acne (n=120) [141] 16 weeks treatment and 8 weeks follow-up; randomized comparative study Higher conventional doses followed by lower dose in severe acne for up to 8 weeks; low doses (20 mg), alternate day is effective and safe Isotret (low cumulative dose); mild to moderate acne (n=150) [142] 2 year follow-up; open, prospective, noncomparative study Effective in inducing stable remission and averts further acne relapses; low cumulative doses are economical and have less AEs Isotret 20 mg daily versus 20 mg alternate days; moderate to severe acne (n=240) [143] 24 weeks treatment and 12 weeks follow-up; prospective randomized comparative study Both effective and well tolerated; 20 mg daily preferred for severe acne Antibiotics Azithro (500 mg); moderate inflammatory acne vulgaris (n=57) [144] 12 weeks; open-label, noncomparative study Safe, effective and better patient compliance Azithro versus Doxy; Moderate acne (n=386) [145] 3 months; RCT Doxy better than Azithro Azithro versus Doxy; moderate acne (n=100) [146] 15 months; randomized, double-blind, clinical trial Comparable efficacy; Doxy better in>18 years old patients Azithro versus Tetra; moderate to severe acne (n=290) [147] 3 months; randomized, investigator-blind, clinical trial Both the antibiotics were effective; Azithro slightly better than Tetra Azithro versus Mino; acne vulgaris (n=72) [148] 6 weeks; open-label, comparative study Almost equally effective and well-tolerated Mino; moderate to severe acne (n=6013) [149] 39 RCTs (Cochrane systematic review) Effective therapy; lack of data for proving superiority to other treatment regimens Mino (ER formulation, 1 mg/kg once daily); moderate to severe acne (n=924 [RCT 1 -n=451, RCT 2 -n=473]) [150] 12 weeks; literature review (multicenter, randomized, double-blind, placebo-controlled, Phase 3 studies) Safe and effective Doxy and Mino; moderate to severe acne [151] Review Enteric-coated Doxy is well-tolerated; better patient compliance Doxy (SD, 20 mg twice daily); moderate acne (n=51) [152] 6 months; multicenter, double-blind, randomized, placebo-controlled, parallel group trial Effective and well tolerated; does not lead to rise in number or severity of resistant strains Doxy (double-scored, 150 mg); moderate to severe acne [153] Review
Low potential for AEs (typical GI); comparable to enteric-coated tablets Levo (500 mg, once daily); inflammatory acne (n=19) [154] 2 weeks; open study Effective and well tolerated Azithro versus Doxy; acne vulgaris (n=51) [155] 3 months; randomized, investigator-blinded study 
Antibiotics
Oral antibiotics are generally preferred in moderate to severe inflammatory acne. [9] They are found to possess antimicrobial as well anti-inflammatory properties. [7, 24, 61] Likewise topical antibiotics, oral antibiotics should also be given in combination with other agents to minimalize the bacterial resistance and enhance treatment outcomes. Generally, they are prescribed in combination with topical retinoids or BPO [ Tables 2 and 6 ]. [60, 61] 
Expert opinion
The management of acne should focus on the treatment of inflammation which supports the use of oral antibiotics in acne. Antibiotics should be used till the inflammation is visible. Afterward, the patients should be managed with isotretinoin.
Mild acne/Grade I should be treated with topical agents such as BPO and retinoids. A 3-month low-dose oral antibiotic treatment (to reduce microbial resistance) can be given to patients if they do not respond to topical agents. Combination of isotretinoin at a higher dose (20-30 mg) and doxycycline is contraindicated (due to risk of pseudotumor cerebri, hair fall, and benign intracranial hypertension). Combination of isotretinoin and azithromycin is preferred in case of Grade III or IV or severe papulopustular acne.
Minocycline seems to far best in terms of least resistance and efficacy; however, reliable evidence does not support its superiority or benefits in acne-resistant to other therapies. Moreover, dose ambiguity, unpredictable safety (risk of phototoxic vestibulotoxic, autoimmune, and hypersensitive reactions), and inconsistent safety benefits of minocycline modified-release (MR) formulations do not substantiate the minocycline use as the first-line drug in acne treatment.
Minocycline and doxycycline are seen to have comparable efficacy. Although gastric intolerance is higher for doxycycline, this can be reduced with enteric-coated or double-scored tablets or using staggered dosing. Low dose doxycycline (subantimicrobial dose 40 mg MR) has been used in treatment of acne and found to prevent development of resistant strains. [157] 24 weeks; single-center randomized double-blind, parallel-group study Safe and effective EE (20 µg)/DRSP (3 mg) COC; moderate acne (n=893) [158] 6 cycles; RCT Effective in reducing acne lesions DSG + EE versus LNG+EE; type not specified (n=100) [159] 1 year; RCT DSG + EE more effective in acne treatment and hirsutism without affecting the weight Flut versus Cypro-EE combination; moderate acne (n=64) [160] 6 months; RCT Flut more effective than Cypro-EE Spirono or combination with steroids (OC pills included); type not specified [161] Cochrane intervention review to assess efficacy in hirsutism and acne
No evidence for effectiveness in acne treatment COC (EE-DRSP) efficacy and safety; mild to moderate acne [65] Review DRSP containing OCs considered as the current standards of hormonal therapy for women with acne Lymecycline is a new drug with low antimicrobial resistance and can show significant benefits in acne treatment. However, it is not used as the first line of therapy due to price and availability issues. Levofloxacin can be used as an anti-acne oral antibacterial due to lowest resistance; however, its anti-inflammatory action is not established.
In case of pregnant women, azithromycin alone is prescribed with or without topical agents. A 3-day course (Friday, Saturday, and Sunday) per week for 6-8 weeks is the best azithromycin regimen (due to 96 h half-life of azithromycin).
Pulse clarithromycin therapy (250 mg twice daily) for 7 days (repeated after a gap of 10 days) has been used in isolated case reports in patients with moderate to severe acne that are ineffective to doxycycline, minocycline, and erythromycin treatment regimen. [62] BPO in combination with oral antibiotics is a beneficial therapy as it reduces the dependence on systemic agents and further prevents the development of P. acnes resistance. [61, 63] 
Antiandrogen therapy
Androgens play a key role in the development of acne vulgaris through the induction of sebum production. [5] Therefore, antiandrogenic therapies can be useful for the management of female patients with moderate to severe acne. The contraceptive hormones have a role in reducing the androgen-induced sebum production. It enhances the production of sex hormone-binding globulin, thereby decreasing the free testosterone (biologically active) levels in women. Contraceptives are preferred in the treatment of hormone-related acne; progestins are particularly recommended despite their no androgen activity [ Tables 2 and 6 ]. [64] [65] [66] Expert opinion Females <14 years or >35 years should be treated with antiandrogens after an opinion of endocrinologist/gynecologist. Oral contraceptives (OCs) are must in women with high androgens and are added to regimen to regularize the menstrual cycle. Women with polycystic ovary syndrome, premenstrual flares, and other clinical signs should be prescribed with antiandrogen therapy (mainly cyproterone) in combination with OCs. Spironolactone is not used in acne because of less role/low evidence of sebocytes in acne. However, in patients with high androgens or with late-onset acne (above 40 years of age), spironolactone can be prescribed as monotherapy in low dose. OC and spironolactone should be tapered down in terms of dose to avoid hair fall. Flutamide is not used because of the associated AEs.
Miscellaneous agents
Oral corticosteroids
Oral corticosteroids are used in cases with late-onset hyperandrogenism (up to 6 months). [67, 68] In case of severe acne, low-dose oral corticosteroids along with low-dose isotretinoin are used. [69, 70] Oral corticosteroids are generally used as a 2-3-week course (0.5-1.0 mg/kg/day methylprednisolone) without tapering down. Low dose of isotretinoin (0.25 mg/kg/day) in combination with oral corticosteroids should be used for 2-3 weeks after which oral corticosteroids should be stopped (over the next 6 weeks), followed by continued isotretinoin at a dose of 0.25 mg/kg/day depending on the condition of the patient. [71] Expert opinion Oral corticosteroids should be used in late-onset hyperandrogenism (up to 6 months). They should be used as a 2-3-week course (20 mg prednisolone or 16 mg methylprednisolone) without tapering down. Low dose of isotretinoin (10-20 mg) in combination with oral corticosteroids should be used for 2-3 weeks after which oral corticosteroids should be stopped followed by continued isotretinoin at a dose of 20 mg. Prednisolone is recommended for premenstrual flares and dexamethasone in cases with congenital adrenal hyperplasia.
Diet
The diet with high glycemic content (milk/dairy product) plays a crucial role in the development of acne and relates to longer duration/persistence of acne. [72] The underlying reasons may be due to the presence of hormone/bioactive molecule in the skimmed milk or insulinotropic effect of milk protein which elevates the serum level of insulin and insulin-like growth factor-1. [73] Further, hyperglycemic diet causes reduction in the levels of adiponectin, which results in upregulation of pro-inflammatory cytokines and downregulation of anti-inflammatory cytokines. [74] [75] [76] [77] It is also responsible for the rise in oxidative stress and decline in serum level of antimicrobial peptide, both of which results in triggering the comedogenesis and eliciting the inflammation. [78] [79] [80] Zinc can be used as an add-on therapy due to its sebosuppressive activity. [81] Omega fatty acids are used as individualized treatment option due to anti-inflammatory or antioxidant effects. [82] Specific Acne Allied Disorders
Acne inversa
Acne inversa (also called hidradenitis suppurativa) is a chronic inflammatory disorder of the regions of apocrine gland (axillary and anogenital). [83] Antibiotics, antiandrogen, and retinoids are useful only in exacerbations of the disease or as the perioperative treatment. [84] Acne exocriee Some acne patients develop the habit of picking their skin (neurotic or psychogenic problem) known as acne excoriee. [85] It can be managed with serotonin reuptake inhibitor antidepressant, a cognitive behavioral method that may provide benefits to such patients. [86] Gram-negative folliculitis GNF is caused due to intercession and substitution of Gram-positive flora of acne affected skin by Gram-negative bacteria. The patients with acne or rosacea who are on prolonged treatment with systemic antibiotics may develop GNF. It is generally noticeable in patients after 3-6 months of ineffective prolonged therapy with oral antiacne antibiotics. Oral isotretinoin (0.5-1 mg/kg daily for 4-5 months) is the most effective cure for GNF in acne or rosacea. [87] 
Conclusion
The four well-known pathogenic factors responsible for acne are generally managed by topical as well as oral therapies. Although topical therapy is the mainstay as well as the first-line treatment prescribed for patients suffering from noninflammatory comedones to moderate inflammatory acne, oral therapies are preferred in cases with severe nodular acne. An early initiation of therapy is directly proportional to effective therapeutic outcomes. However, the complexity of the disease as well as interpatient differences warrants combination of various agents to be followed. There is a need to develop a daytime applicable dermato-cosmetic product for both, active acne and maintenance therapy, with mattifying effects. Incorporation of cosmetic daily regimen would result in affluent application of product and improved patient adherence which would further make the clinicians and patients overlook the cost involved in combined therapies.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.
What is new?
First Indian Expert Opinion based on clinical evidence and clinical expertise which provides a practical module for in clinic use addressing; • Place and positioning along with the rationality of all available topical and oral acne therapies in India.
• Provides insights on combination vs monotherapy their class, strength comparison along with formulation innovations.
• Particularized role of adjunctive therapies (face wash, moisturizer and miscellaneous topical therapy) along with their do's and don'ts in acne management.
